Join Now

Category Archives: BioUtah News

GE HealthCare Awarded a $44 Million Grant to Develop Artificial Intelligence-Assisted Ultrasound Technology Aimed at Improving Outcomes in Low-and-Middle-Income Countries

rant from Bill & Melinda Gates Foundation will facilitate development of AI-assisted applications and tools

| Tagged | Comments Off on GE HealthCare Awarded a $44 Million Grant to Develop Artificial Intelligence-Assisted Ultrasound Technology Aimed at Improving Outcomes in Low-and-Middle-Income Countries

BioUtah, Life Sciences Innovators Take Stage at Legislature’s Interim Meeting

The Utah Life Sciences Innovation Caucus hosted a lunch for all legislators during the September 18.

| Comments Off on BioUtah, Life Sciences Innovators Take Stage at Legislature’s Interim Meeting

NUSANO APPOINTS INDUSTRY EXPERT ALEXANDRE GIBIM AS CHIEF OPERATIONS OFFICER

EXECUTIVE WITH THREE DECADES OF SUCCESSFUL MULTINATIONAL OPERATIONS AND COMMERCIAL EXPERIENCE TO LEAD LAUNCH OF PROPRIETARY RADIOISOTOPE PRODUCTION PLATFORM

| Tagged | Comments Off on NUSANO APPOINTS INDUSTRY EXPERT ALEXANDRE GIBIM AS CHIEF OPERATIONS OFFICER

BioUtah Participates in American Cancer Society Policy Panel Presentation

Kelvyn Cullimore, BioUtah’s CEO, participated as a panelist.

| Comments Off on BioUtah Participates in American Cancer Society Policy Panel Presentation

Merit Medical Launches the Aspira® Evacuated Drainage Bottle

Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients

| Tagged | Comments Off on Merit Medical Launches the Aspira® Evacuated Drainage Bottle

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.

| Tagged | Comments Off on Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence

| Tagged | Comments Off on New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.

| Tagged | Comments Off on Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Ultradent Named a Fortune Magazine Top Workplace for Third Straight Year

Ultradent Products is being recognized for the third consecutive year as a Fortune Magazine Top Large Workplace in Manufacturing and Production.

| Tagged | Comments Off on Ultradent Named a Fortune Magazine Top Workplace for Third Straight Year

Academia in Action: Searching for rare disease treatments

By their very nature, rare diseases impact a smaller portion of the population compared to conditions like cancer or the flu. While these diseases are less common, those affected by them, along with University of Utah researchers, are actively searching for a cure. Treating patients as individuals: Clement Chow Read more about Clement Chow’s research […]

| Comments Off on Academia in Action: Searching for rare disease treatments

CLENE REPORTS SIGNIFICANTLY IMPROVED SURVIVAL BENEFIT OF 19.3 MONTHS AND SIGNIFICANTLY DELAYED CLINICAL WORSENING IN RESCUE-ALS OPEN-LABEL EXTENSION TWO YEAR FOLLOW-UP

19.3 month significant survival difference for CNM-Au8® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au8 treatment exposure without any identified safety signals SALT LAKE CITY, Aug. 29, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc., today announced […]

| Comments Off on CLENE REPORTS SIGNIFICANTLY IMPROVED SURVIVAL BENEFIT OF 19.3 MONTHS AND SIGNIFICANTLY DELAYED CLINICAL WORSENING IN RESCUE-ALS OPEN-LABEL EXTENSION TWO YEAR FOLLOW-UP

BioTuesdays Features Halia Therapeutics CEO

In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]

| Tagged | Comments Off on BioTuesdays Features Halia Therapeutics CEO